|
|
|
| 1 |
8,466,162 |
5-alkynyl-pyridines
|
| 2 |
8,466,151 |
Compounds and method for treatment of cancer
|
| 3 |
8,466,150 |
Inhibitors of poly(ADP-ribose)polymerase
|
| 4 |
8,466,146 |
Cyclothiocarbamate derivatives as progesterone receptor modulators
|
| 5 |
8,461,168 |
Process for the preparation of pyrimidine derivatives
|
| 6 |
8,445,506 |
Polymorphs of lopinavir
|
| 7 |
8,440,824 |
Method for producing pyrimidine compound
|
| 8 |
8,440,663 |
4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2
modulators and methods of use
|
| 9 |
RE44,205 |
Adenosine A.sub.2a receptor antagonists
|
| 10 |
8,436,038 |
Indole and indazole compounds as an inhibitor of cellular necrosis
|
| 11 |
8,436,006 |
2-amino-quinazoline derivatives useful as inhibitors of .beta.-secretase
(BACE)
|
| 12 |
8,431,594 |
Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
|
| 13 |
8,431,588 |
Cyclopropyl polymerase inhibitors
|
| 14 |
8,431,576 |
Heterocyclic compounds for the treatment of neurological and psychological
disorders
|
| 15 |
8,431,575 |
Phenyl-heteroaryl derivatives and methods of use thereof
|
| 16 |
8,426,446 |
Acrylamide derivative and use thereof in manufacture of medicament
|
| 17 |
8,426,433 |
Anticoagulant compounds, pharmaceutical compositions on their basis to
treat thrombotic conditions, and plasma-substituting solution to correct
hypercoagulation defects of hemodilution
|
| 18 |
8,426,429 |
2-amino-quinazoline derivatives useful as inhibitors of .beta.-secretase
(BACE)
|
| 19 |
8,420,659 |
Compositions and methods for inhibition of the JAK pathway
|
| 20 |
8,420,656 |
Substituted 5-fluoro-1H-pyrazolopyridines and their use
|
| 21 |
8,420,653 |
Pyrimidine compounds and their uses
|
| 22 |
8,420,643 |
Compounds and method for treatment of cancer
|
| 23 |
8,415,381 |
Heteroaryl compounds and their uses
|
| 24 |
8,415,367 |
Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
|
| 25 |
8,415,357 |
Compounds with anti-cancer activity
|
| 26 |
8,415,340 |
Triazine kinase inhibitors
|
| 27 |
8,415,265 |
Method for producing melamine
|
| 28 |
8,410,127 |
Substituted
tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
| 29 |
8,410,126 |
Pyrimidine inhibitors of PKTK2
|
| 30 |
8,410,124 |
Deuterated etravirine
|
| 31 |
8,410,122 |
Bicyclic heterocycle derivatives and methods of use thereof
|
| 32 |
8,410,089 |
Fused heterocyclic ring compound
|
| 33 |
8,404,870 |
((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and
process for the production thereof
|
| 34 |
8,399,469 |
Low hygroscopic aripiprazole drug substance and processes for the
preparation thereof
|
| 35 |
8,399,450 |
Compounds and compositions as protein kinase inhibitors
|
| 36 |
8,399,448 |
6-amino-pyrimidine-4-carboxamide derivatives and related compounds which
bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of
multiple sclerosis
|
| 37 |
8,399,433 |
Amino pyrimidine anticancer compounds
|
| 38 |
8,394,956 |
Process for preparing pyrimidine propenaldehyde
|
| 39 |
8,394,809 |
Phenoxy-substituted pyrimidines as opioid receptor modulators
|
| 40 |
8,389,534 |
Pyrimidine non-classical cannabinoid compounds and related methods of use
|
| 41 |
8,383,639 |
HIV integrase inhibitors
|
| 42 |
8,383,629 |
Inhibitors of 11.beta.-hydroxysteroid dehydrogenase type 1
|
| 43 |
8,383,627 |
Crystalline polymorph of doxazosin mesylate (form IV) and process for
preparation thereof
|
| 44 |
8,377,973 |
Compositions and processes for preparing 5-amino or substituted amino
1,2,3-triazoles and triazole orotate formulations
|
| 45 |
8,377,950 |
Crystalline form of
5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolid-
ine-2,4-dione potassium salt
|
| 46 |
8,377,924 |
Protein kinase C inhibitors and uses thereof
|
| 47 |
8,377,921 |
Compounds and compositions as protein kinase inhibitors
|
| 48 |
8,372,974 |
Regioselective preparation of substituted pyrimidines
|
| 49 |
8,372,865 |
Dihydropyridone amides as P2X.sub.7 modulators
|
| 50 |
8,372,858 |
Compounds and compositions as protein kinase inhibitors
|
